184 related articles for article (PubMed ID: 10575653)
1. Cytochromes P450 and cancer.
Kaminsky LS; Spivack SD
Mol Aspects Med; 1999; 20(1-2):70-84, 137. PubMed ID: 10575653
[No Abstract] [Full Text] [Related]
2. [Polymorphism and the level of P450 gene expression in xenobiotic metabolism].
Niemira M; Wiśniewska A; Mazerska Z
Postepy Biochem; 2009; 55(3):279-89. PubMed ID: 19928584
[TBL] [Abstract][Full Text] [Related]
3. [Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility].
Gu YF; Zhang ZD; Zhang SC; Zheng SH; Jia HY; Gu SX
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3064-8. PubMed ID: 18261353
[TBL] [Abstract][Full Text] [Related]
4. Molecular genetics of the human cytochrome P450 monooxygenase superfamily.
Smith G; Stubbins MJ; Harries LW; Wolf CR
Xenobiotica; 1998 Dec; 28(12):1129-65. PubMed ID: 9890157
[No Abstract] [Full Text] [Related]
5. [Association between genetic polymorphism and lung cancer risk].
Ariyoshi N; Kitada M; Kamataki T
Nihon Rinsho; 2002 May; 60 Suppl 5():46-9. PubMed ID: 12101715
[No Abstract] [Full Text] [Related]
6. CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer.
Silvestri L; Sonzogni L; De Silvestri A; Gritti C; Foti L; Zavaglia C; Leveri M; Cividini A; Mondelli MU; Civardi E; Silini EM
Int J Cancer; 2003 Apr; 104(3):310-7. PubMed ID: 12569554
[TBL] [Abstract][Full Text] [Related]
7. Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: some answers but still questions.
Wilkinson GR
Clin Pharmacol Ther; 2004 Aug; 76(2):99-103. PubMed ID: 15289786
[No Abstract] [Full Text] [Related]
8. Expression of cytochrome P450 enzymes CYP1A1, CYP1B1, CYP2E1 and CYP4B1 in cultured transitional cells from specimens of the human urinary tract and from urinary sediments.
Roos PH; Belik R; Föllmann W; Degen GH; Knopf HJ; Bolt HM; Golka K
Arch Toxicol; 2006 Jan; 80(1):45-52. PubMed ID: 16341845
[TBL] [Abstract][Full Text] [Related]
9. Effects of tobacco smoke on the gene expression of the Cyp1a, Cyp2b, Cyp2e, and Cyp3a subfamilies in mouse liver and lung: relation to single strand breaks of DNA.
Villard PH; Seree EM; Re JL; De Meo M; Barra Y; Attolini L; Dumenil G; Catalin J; Durand A; Lacarelle B
Toxicol Appl Pharmacol; 1998 Feb; 148(2):195-204. PubMed ID: 9473526
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: regulation and toxicological significance.
Rannug A; Alexandrie AK; Persson I; Ingelman-Sundberg M
J Occup Environ Med; 1995 Jan; 37(1):25-36. PubMed ID: 7620940
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphism of xenobiotic metabolising enzymes in Slovenian lung cancer patients.
Dolzan V; Rudolf Z; Breskvar K
Pflugers Arch; 2000; 439(3 Suppl):R29-30. PubMed ID: 10653131
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 pharmacogenetics and cancer.
Rodriguez-Antona C; Ingelman-Sundberg M
Oncogene; 2006 Mar; 25(11):1679-91. PubMed ID: 16550168
[TBL] [Abstract][Full Text] [Related]
13. Oxidation of xenobiotics by recombinant human cytochrome P450 1B1.
Shimada T; Gillam EM; Sutter TR; Strickland PT; Guengerich FP; Yamazaki H
Drug Metab Dispos; 1997 May; 25(5):617-22. PubMed ID: 9152602
[TBL] [Abstract][Full Text] [Related]
14. [Clinical significance of some genetic polymorphisms of cytochrome P-450: family CYP1 and subfamilies CYP2A, CYP2B and CYP2C].
Wojtczak A; Skretkowicz J
Pol Merkur Lekarski; 2009 Mar; 26(153):248-52. PubMed ID: 19388543
[TBL] [Abstract][Full Text] [Related]
15. Significance of genetic polymorphisms in cancer susceptibility.
Hietanen E
Adv Exp Med Biol; 1999; 472():241-51. PubMed ID: 10736631
[No Abstract] [Full Text] [Related]
16. Evidence-based prevention (EBP): approach to lung cancer prevention based on cytochrome 1A1 and cytochrome 2E1 polymorphism.
Oyama T; Matsumoto A; Isse T; Kim YD; Ozaki S; Osaki T; Sugio K; Yasumoto K; Kawamoto T
Anticancer Res; 2003; 23(2C):1731-7. PubMed ID: 12820449
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450-null mice.
Buters JT; Doehmer J; Gonzalez FJ
Drug Metab Rev; 1999 May; 31(2):437-47. PubMed ID: 10335446
[No Abstract] [Full Text] [Related]
18. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma.
Gajecka M; Rydzanicz M; Jaskula-Sztul R; Kujawski M; Szyfter W; Szyfter K
Mutat Res; 2005 Jul; 574(1-2):112-23. PubMed ID: 15914211
[TBL] [Abstract][Full Text] [Related]
19. [Cancer pharmacogenetics: study of genetically determined variations on cancer susceptibility due to xenobiotic exposure].
Quiñones L; Lee K; Varela F N; Escala M; García K; Godoy L; Castro A; Soto J; Saavedra I; Cáceres D
Rev Med Chil; 2006 Apr; 134(4):499-515. PubMed ID: 16758088
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms in the human cytochrome P450 and arylamine N-acetyltransferase: susceptibility to head and neck cancers.
Khlifi R; Messaoud O; Rebai A; Hamza-Chaffai A
Biomed Res Int; 2013; 2013():582768. PubMed ID: 24151610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
